Results
After
removing duplicates, in total of
62 severe DDI pairs of LPV/RTV were identified from the FDA and
Liverpool COVID-19 interaction resources predicted to cause clinically
significant life-threatening ADRs, as shown in Figure 1. Of these, seven
unique DDI pairs were identified from the FDA only whereas 45 unique DDI
pairs were identified from the Liverpool COVID-19 drug interactions
resource. Interestingly, only 10 DDI pairs were recognized by both of
these drug interaction resources. The lists of all interacting drugs as
identified from these two DDI resources are shown in Table 1.
Systematic cross-comparison between these two well-recognized
evidenced-based DDI resources indicated that discrepancies were existed
in between these two resources for enlisting contraindicated drugs
potentially causing life-threatening ADRs of LPV/RTV.
Severe DDI pairs that were not enlisted by the Liverpool COVID-19 DDI
resource and the potential
life-threatening ADRs are
tabulated in Table 2 as identified from the FDA prescribing information
of LPV/RTV. Notable life-threatening ADRs due DDIs of LPV/RTV with these
drugs were cardiac arrhythmias, vasospasm, ischemia and hypotension.
Severe DDI pairs that were recognized by both the FDA and the Liverpool
COVID-19 DDI resource and the potential life-threatening ADRs are
tabulated in Table 3. Notable life-threatening ADRs due DDIs of LPV/RTV
with these drugs were cardiac arrhythmias, myopathy, rhabdomyolysis,
respiratory depression, risk of alanine transaminase (ALT) elevations,
hypotension and risk of reduced virologic response.
In summary, Liverpool COVID-19 DDI resource was more effective in
enlisting contraindicated drugs of LPV/RTV potentially causing
life-threatening ADRs, however, clinicians should not entirely rely on
this resource for checking DDIs of LPV/RTV since it didn’t enlist
several important contraindicated drugs of LPV/RTV predicted to cause
life-threatening ADRs.